This results in a significant reduction in the capacity to use long-chain fatty acids as energy substrate, as typically observed in fibroblasts from patients with the myopathic form of CPT2 or VLCAD deficiency [13,14]. This evidence concerns the gene CPT2 and very long chain acyl-CoA dehydrogenase deficiency.